Capital Group Investment Management PTE. LTD. Purchases 1,089 Shares of Eli Lilly and Company $LLY

Key Points

• Capital Group Investment Management PTE. LTD. increased its Eli Lilly stake by 7.2% in the fourth quarter, adding 1,089 shares to reach 16,150 shares worth about $17.36 million.
• Institutional ownership remains high, with 82.53% of Eli Lilly shares held by institutions and hedge funds, and several other firms also reported recent buying activity.
• Analysts remain broadly positive on LLY, with a Moderate Buy consensus and an average price target of $1,227, while the company also posted strong quarterly results and raised attention around its obesity-drug pipeline and CVS coverage win for Zepbound.

Capital Group Investment Management PTE. LTD. raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 16,150 shares of the company's stock after buying an additional 1,089 shares during the quarter. Eli Lilly and Company comprises about 2.8% of Capital Group Investment Management PTE. LTD.'s holdings, making the stock its 6th largest position. Capital Group Investment Management PTE. LTD.'s holdings in Eli Lilly and Company were worth $17,356,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of LLY. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. grew its stake in shares of Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock worth $6,231,000 after purchasing an additional 1,141 shares during the period. Flow Traders U.S. LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth $356,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth $749,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LLY. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an "overweight" rating in a research note on Friday, May 1st. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Friday. Guggenheim reaffirmed a "buy" rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 2nd. Finally, Freedom Capital upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,227.00.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,133.15 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,166.29. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm's 50-day simple moving average is $974.59 and its 200 day simple moving average is $1,013.04. The firm has a market capitalization of $1.07 trillion, a PE ratio of 40.25, a P/E/G ratio of 1.24 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm's quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is presently 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.